Target of oncology anti-angiogenics (bevacizumab) & ophthalmic anti-VEGF biologics (ranibizumab, aflibercept, faricimab) in wet AMD & diabetic retinopathy
Gene Structure & Expression
Genomic Organization & Cytogenetic Locus: 8-exon gene spanning 16.3 kb on chromosome 6p21.1 with a 5-prime hypoxia response element (HRE) bound by HIF-1alpha (HIF1A) and an ERR-alpha/PGC-1alpha (PPARGC1A) response element; alternative splicing of exons 6 and 7 (which encode basic heparin/neuropilin-1-binding domains) generates freely diffusible VEGF121, intermediate matrix/cell-bound VEGF165 (the predominant physiological isoform), and tightly matrix-sequestered VEGF189/VEGF206.
Cellular & Tissue Expression Profile: Secreted by hypoxic or metabolically active parenchymal cells including exercising skeletal muscle fibers, cardiac myocytes, retinal pigment epithelium and Muller glia, renal glomerular podocytes, tumor cells, and wound macrophages.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: Binds endothelial receptor tyrosine kinases VEGFR-1 (FLT1, which acts partly as a high-affinity decoy) and VEGFR-2 (KDR / Flk-1, the principal signaling receptor) alongside co-receptor Neuropilin-1, triggering VEGFR-2 dimerization and Tyr1175 phosphorylation to activate PLC-gamma-PKC-ERK (endothelial proliferation), PI3K-AKT1-NOS3 (nitric oxide synthesis and cell survival), and Src-VE-cadherin phosphorylation (vascular permeability).
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Remarkably dosage-sensitive during embryogenesis: loss of even a single VEGFA allele (haploinsufficiency) is embryonically lethal at mid-gestation due to defective blood-island vasculogenesis and dorsal aorta formation; in adult skeletal muscle, exercise-induced PGC-1alpha drives VEGFA transcription to expand capillary-to-fiber ratio and VO2max.
Therapeutic & Clinical Pharmacology: Clinically neutralized in solid oncology by bevacizumab (Avastin) and ramucirumab, and revolutionized ophthalmology via intravitreal anti-VEGF biologics—ranibizumab (Lucentis), aflibercept (Eylea), brolucizumab, and dual VEGF/Ang-2 bispecific faricimab (Vabysmo)—as well as subretinal/intravitreal AAV anti-VEGF gene therapies (ABBV-RGX-314, ixoberogene soroparvovec) for neovascular age-related macular degeneration and diabetic macular edema.